Latest Trials Latest NewsFAQ

EMORY UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1836-12-10

Employees: 10K

Market Cap: -

Website: http://www.emory.edu

Clinical Trials

A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Vorinostat

First Posted Date: 2009-12-24

Last Posted Date: 2021-11-03

Lead Sponsor: Emory University

Target Recruit Count: 30

Registration Number: NCT01038388

Locations: 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States

Melatonin and the Metabolic Syndrome

Phase 2

Completed

Conditions: Metabolic Syndrome

Interventions: Drug: Placebo
Drug: Melatonin

First Posted Date: 2009-12-24

Last Posted Date: 2015-02-27

Lead Sponsor: Emory University

Target Recruit Count: 39

Registration Number: NCT01038921

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Emory Hospital, Atlanta, Georgia, United States

Trial on Safety and Pharmacokinetics of Intravaginal Curcumin

Phase 1

Completed

Conditions: Uterine Cervical Dysplasia

Interventions: Drug: curcumin

First Posted Date: 2009-12-18

Last Posted Date: 2013-11-28

Lead Sponsor: Emory University

Target Recruit Count: 13

Registration Number: NCT01035580

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States

S.T.A.R.S.: Sistas Talking About Real Solutions

Phase 1

Completed

Conditions: HIV Prevention

Interventions: Behavioral: General Health & Nutrition

First Posted Date: 2009-12-09

Last Posted Date: 2013-12-17

Lead Sponsor: Emory University

Target Recruit Count: 855

Registration Number: NCT01028157

Locations: 🇺🇸
Emory University, Rollins School of Public Health, Atlanta, Georgia, United States

Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients

Phase 4

Completed

Conditions: Sepsis

Interventions: Drug: Doripenem

First Posted Date: 2009-12-09

Last Posted Date: 2014-01-27

Lead Sponsor: Emory University

Target Recruit Count: 30

Registration Number: NCT01027897

Locations: 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States

Evaluation of GSK561679 in Women With Post-Traumatic Stress Disorder

Phase 2

Completed

Conditions: Stress Disorders, Post-Traumatic

Interventions: Drug: GSK561679
Drug: Placebo

First Posted Date: 2009-11-25

Last Posted Date: 2017-03-07

Lead Sponsor: Emory University

Target Recruit Count: 267

Registration Number: NCT01018992

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Stress and Health Research Program, San Francisco VA Medical Center, University of California San Francisco, San Francisco, California, United States
🇺🇸
Mount Sinai School of Medicine, New York, New York, United States

and more 1 locations

Effect of HIV Infection and Highly Active Antiretroviral Treatment (HAART) on Bone Homeostasis

Completed

Conditions: Osteopenia
Osteoporosis
HIV Infection

First Posted Date: 2009-11-25

Last Posted Date: 2015-10-19

Lead Sponsor: Emory University

Target Recruit Count: 120

Registration Number: NCT01020045

Locations: 🇺🇸
Grady Infectious Diseases Program Clinic, Atlanta, Georgia, United States

DPP-4 Inhibition and TZD for DM Prevention

Not Applicable

Terminated

Conditions: Prediabetic State

Interventions: Drug: PLACEBO
Drug: Sitagliptin + Pioglitazone PLACEBO
Drug: Sitagliptin + Pioglitazone

First Posted Date: 2009-11-01

Last Posted Date: 2013-12-05

Lead Sponsor: Emory University

Target Recruit Count: 3

Registration Number: NCT01006018

Locations: 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)

Phase 1

Terminated

Conditions: Lymphoma, Small Lymphocytic
Leukemia, Lymphocytic, Chronic, B-Cell
Chronic Lymphocytic Leukemia

Interventions: Drug: Lenalidomide, Rituximab, and Cyclophosphamide

First Posted Date: 2009-11-01

Last Posted Date: 2014-08-13

Lead Sponsor: Emory University

Target Recruit Count: 6

Registration Number: NCT01005979

Locations: 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States

Diabetes Group Visits

Completed

Conditions: Diabetes

First Posted Date: 2009-10-23

Last Posted Date: 2014-07-09

Lead Sponsor: Emory University

Target Recruit Count: 92

Registration Number: NCT01000363

Locations: 🇺🇸
Grady North DeKalb Clinic, Chamblee, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy